Strong IP keeps collaboration alive, allowing companies to attract capital, strike partnerships, and bring innovations to patients, according to legal experts at Ice Miller.

Tom Wells at 4C Associates, explores the future of biologistics, or how the packaging, storage, and logistics for biologics ...

On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into ...

Leadership means knowing when to jump in and when to let someone else worry about the details, writes Hope Mueller, SVP of Corporate Development and Strategy at Currax Pharmaceuticals.

Since clinical trials have become increasingly complex with more data being collected, this consequently puts more pressure on sponsors to improve efficiencies while still maintaining quality.

AI is becoming increasingly sophisticated, taking on responsibilities that were once exclusive to human beings. However, there are also disadvantages posed by ethical ...

Life Science industry experts from Life Science Leaders editorial advisory board answer your questions ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

Kelsey Mullady Unfortunately, too often organizations treat the compliance department as an afterthought and scramble to get practices into place just in time. Worse yet, many organizations silo the ...

The life sciences industry, composed of pharmaceuticals, biotechnology, and medical devices, advances healthcare to improve the quality of life for people worldwide. However, as investment in the life ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...